Earth Science Tech, Inc. (OTC: ETST) has announced the acquisition of Zoolzy LLC, a Florida-based wholesale distributor of active pharmaceutical ingredients (APIs) and finished FDA-approved prescription products. This move is set to enhance ETST's supply chain capabilities and broaden its market reach, particularly in the veterinary sector.
Zoolzy operates from a 3,684-square-foot facility in Doral, Florida, and is expected to integrate seamlessly into ETST's existing operations. By securing a direct line to APIs at competitive wholesale prices, ETST's compounding pharmacies can potentially increase their profit margins. The acquisition also provides ETST with access to novel APIs that can be used for custom compounding, allowing the company to offer more specialized pharmaceutical solutions.
One of the key strategic advantages of this acquisition is the immediate procurement access to common veterinary medications. ETST plans to leverage this new supply line to expand into the animal health market, introducing unique, flavored, and easy-to-administer veterinary therapeutics. This initiative will be led by members of ETST's management team who have experience and established networks in the exotic wildlife space, positioning the company to capitalize on a niche but growing market segment.
The acquisition aligns with ETST's broader strategy of building a vertically integrated healthcare platform. By combining compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment, ETST aims to create a seamless experience for patients. The integration of Zoolzy's distribution capabilities strengthens this model by ensuring a reliable and cost-effective supply of essential ingredients.
Earth Science Tech operates as a diversified holding company focused on the health and wellness sector. The company's principal operating strategy is to build a comprehensive healthcare ecosystem that supports patient care from consultation to fulfillment. This acquisition is a testament to that commitment, as it enhances the company's ability to control its supply chain and expand into new therapeutic areas.
The veterinary market represents a significant opportunity for ETST. With the increasing demand for specialized animal health products, the company is well-positioned to introduce innovative solutions. The management's expertise in exotic wildlife adds a unique dimension to this expansion, potentially allowing ETST to serve a wide range of animal species with tailored medications.
Investors and stakeholders will be watching closely to see how this acquisition impacts ETST's financial performance and market position. The company's newsroom provides the latest updates and developments regarding ETST, and more information can be found at https://ibn.fm/ETST. For the full press release, visit https://ibn.fm/nHFqQ.
